To pursue targeted delivery of Covid-19 coronavirus antigens to antigen presenting cells in the form of nanobody-antigen adducts in the presence of approved adjuvants to elicit protective B- and T-cell (inluding CD8) responses as a possible vaccine strategy.
- Funded by Emergent Ventures Fast Grants
- Total publications:0 publications
Grant number: unknown
Grant search
Key facts
Disease
COVID-19Start & end year
N/AFunder
Emergent Ventures Fast GrantsPrincipal Investigator
Dr. Hidde PloeghResearch Location
United States of AmericaLead Research Institution
Harvard UniversityResearch Priority Alignment
N/A
Research Category
Vaccines research, development and implementationResearch Subcategory
N/ASpecial Interest Tags
N/AStudy Type
UnspecifiedClinical Trial Details
N/ABroad Policy Alignment
PendingAge Group
Not ApplicableVulnerable Population
Not applicableOccupations of Interest
Not applicable